EyePoint (EYPT) Free Cash Flow (2010 - 2026)
EyePoint (EYPT) posted Free Cash Flow of -$80.6 million for Q1 2026, down 18.18% sequentially from -$68.2 million in Q4 2025, and down 51.7% YoY from -$167.0 million in Q1 2025.
Analysis
EyePoint (EYPT) Free Cash Flow (2010 - 2026) Analysis & Trends
EyePoint has reported Free Cash Flow for 17 years, with the latest figure at -$80.6 million in Q1 2026.
- Quarterly Free Cash Flow fell 51.7% year-over-year to -$80.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$270.9 million (down 78.52% YoY) and the FY2025 annual result came in at -$243.4 million, down 86.82% from the prior year.
- Free Cash Flow fell to -$80.6 million in Q1 2026 per EYPT's latest filing, from -$68.2 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $57.5 million in Q2 2023 and troughed at -$80.6 million in Q1 2026.
- A 5-year average of -$30.6 million and a median of -$23.1 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow jumped 397.33% in 2023, then plunged 215.19% in 2025.
- Over 5 years, Free Cash Flow stood at -$13.2 million in 2022, then sank by 75.43% to -$23.1 million in 2023, then tumbled by 62.18% to -$37.5 million in 2024, then plunged by 82.08% to -$68.2 million in 2025, then slipped by 18.18% to -$80.6 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$80.6 million, -$68.2 million, and -$59.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | -62.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -62.41 Mn |
| Mar 31, 2026 | -83.91 Mn |
| Dec 31, 2025 | -66.03 Mn |
| Sep 30, 2025 | -60.15 Mn |
| Jun 30, 2025 | -63.81 Mn |
| Mar 31, 2025 | -53.40 Mn |
| Dec 31, 2024 | -38.01 Mn |
| Sep 30, 2024 | -40.60 Mn |
| Jun 30, 2024 | -21.08 Mn |
| Mar 31, 2024 | -32.37 Mn |
| Dec 31, 2023 | -23.99 Mn |
| Sep 30, 2023 | -16.92 Mn |
| Jun 30, 2023 | 56.63 Mn |
| Mar 31, 2023 | -17.32 Mn |
| Dec 31, 2022 | -13.17 Mn |
| Sep 30, 2022 | -14.33 Mn |
| Jun 30, 2022 | -19.34 Mn |
| Mar 31, 2022 | -20.31 Mn |
| Dec 31, 2021 | -16.67 Mn |
| Sep 30, 2021 | -7.92 Mn |